Drug Profile
Influenza virus vaccine intranasal - Acambis/Evans Vaccines
Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Acambis; Evans Vaccines
- Developer Acambis; Evans Vaccines; West Pharmaceutical Services Drug Delivery and Clinical Research Centre
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 11 Dec 2000 Peptide Therapeutics is now called Acambis
- 24 Oct 2000 PowderJect Pharmaceuticals has acquired Medeva's vaccines business from Celltech and now calls it Evans Vaccines
- 22 Jul 1998 Discontinued-I for Influenza virus infections in United Kingdom (Intranasal)